Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells

Experimental Hematology and Oncology

Volumn 3, Issue 1, 2014, Pages

  Cang, Shundong ^a   Ma, Yuehua ^a   Chiao, Jen wei ^b   Liu, Delong ^a,b  

^a ZHENGZHOU UNIVERSITY   (China)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; BETA ACTIN; BETA TUBULIN; CYCLIN DEPENDENT KINASE 1; HISTONE DEACETYLASE 6; HISTONE H3; HISTONE H4; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PACLITAXEL; PHENETHYL ISOTHIOCYANATE; PROTEIN BAX; PROTEIN BCL 2;

ACETYLATION; APOPTOSIS; ARTICLE; BREAST CANCER; CELL CYCLE ARREST; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENTIATION; EPIGENETICS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 84978023495     PISSN: None     EISSN: 21623619     Source Type: Journal    
DOI: 10.1186/2162-3619-3-5     Document Type: Article

References (52)

1. Wolffe AP, Matzke MA. Epigenetics: regulation through repression. Science 1999, 286(5439):481-486. 10.1126/science.286.5439.481, 10521337.
2. Workman JL, Kingston RE. Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu Rev Biochem 1998, 67:545-579. 10.1146/annurev.biochem.67.1.545, 9759497.
3. Ura K, Kurumizaka H, Dimitrov S, Almouzni G, Wolffe AP. Histone acetylation: influence on transcription, nucleosome mobility and positioning, and linker histone-dependent transcriptional repression. EMBO J 1997, 16(8):2096-2107. 10.1093/emboj/16.8.2096, 1169812, 9155035.
4. Bird AP, Wolffe AP. Methylation-induced repression-belts, braces, and chromatin. Cell 1999, 99(5):451-454. 10.1016/S0092-8674(00)81532-9, 10589672.
5. Gutierrez S, Romero-Oliva F. Epigenetic changes: a common theme in acute myelogenous leukemogenesis. J Hematol Oncol 2013, 6(1):57. 10.1186/1756-8722-6-57, 3751780, 23938080.
6. Chakraborty AR, Robey RW, Luchenko VL, Zhan Z, Piekarz RL, Gillet JP, Kossenkov AV, Wilkerson J, Showe LC, Gottesman MM, et al. MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with a MEK inhibitor. Blood 2013, 121(20):4115-4125. 10.1182/blood-2012-08-449140, 23532732.
7. Sherman EJ, Su YB, Lyall A, Schoder H, Fury MG, Ghossein RA, Haque S, Lisa D, Shaha AR, Tuttle RM, et al. Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma. Thyroid 2013, 23(5):593-599. 10.1089/thy.2012.0393, 23186033.
8. Pleyer L, Stauder R, Burgstaller S, Schreder M, Tinchon C, Pfeilstocker M, Steinkirchner S, Melchardt T, Mitrovic M, Girschikofsky M, et al. Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. J Hematol Oncol 2013, 6(1):32. 10.1186/1756-8722-6-32, 3655844, 23627920.
9. van der Helm L, Scheepers E, Veeger N, Daenen S, Mulder A, van den Berg E, Vellenga E, Huls G. Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients. J Hematol Oncol 2013, 6(1):29. 10.1186/1756-8722-6-29, 3639930, 23587459.
10. Gojo I, Tan M, Fang HB, Sadowska M, Lapidus R, Baer MR, Carrier F, Beumer JH, Anyang BN, Srivastava RK, et al. Translational phase I trial of vorinostat (Suberoylanilide Hydroxamic Acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. Clin Cancer Res 2013, 19(7):1838-1851. 10.1158/1078-0432.CCR-12-3165, 23403629.
11. Xu S, De Veirman K, Evans H, Santini GC, Vande Broek I, Leleu X, De Becker A, Van Camp B, Croucher P, Vanderkerken K, et al. Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo. Acta Pharmacol Sin 2013, 34(5):699-709. 10.1038/aps.2012.182, 23564084.
12. Fianchi L, Criscuolo M, Lunghi M, Gaidano G, Breccia M, Levis A, Finelli C, Santini V, Musto P, Oliva E, et al. Outcome of therapy-related myeloid neoplasms treated with azacitidine. J Hematol Oncol 2012, 5(1):44. 10.1186/1756-8722-5-44, 3419605, 22853048.
13. Reimer P, Chawla S. Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral t-cell lymphoma. J Hematol Oncol 2013, 6(1):69. 10.1186/1756-8722-6-69, 3846498, 24020452.
14. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991, 83(24):1797-1805.
15. Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, Rizzo J, Craig J, Phillips J, Von HD. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 1991, 9(7):1261-1267.
16. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989, 111(4):273-279. 10.7326/0003-4819-111-4-273, 2569287.
17. Jordan MA, Kamath K. How do microtubule-targeted drugs work? An overview. Curr Cancer Drug Targets 2007, 7(8):730-742. 10.2174/156800907783220417, 18220533.
18. Fuchs DA, Johnson RK. Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer TreatRep 1978, 62(8):1219-1222.
19. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980, 77(3):1561-1565. 10.1073/pnas.77.3.1561, 348536, 6103535.
20. Schiff PB, Horwitz SB. Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated proteins. Biochemistry 1981, 20(11):3247-3252. 10.1021/bi00514a041, 6113842.
21. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277(5698):665-667. 10.1038/277665a0, 423966.
22. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995, 92(10):4507-4511. 10.1073/pnas.92.10.4507, 41973, 7753834.
23. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987, 47(9):2486-2493.
24. Wiernik PH, Schwartz EL, Einzig A, Strauman JJ, Lipton RB, Dutcher JP. Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 1987, 5(8):1232-1239.
25. Olivotto IA, Whelan TJ, Parpia S, Kim D-H, Berrang T, Truong PT, Kong I, Cochrane B, Nichol A, Roy I, et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol 2013, 31. doi:10.1200/JCO.2013.1250.5511.
26. Chiang H-C, Nair S, Yeh I-T, Santillan A, Hu Y, Elledge R, Li R. Association of radiotherapy with preferential depletion of luminal epithelial cells in a BRCA1 mutation carrier. Exp Hematol Oncol 2012, 1(1):31. 10.1186/2162-3619-1-31, 3514114, 23210696.
27. Incorvati J, Shah S, Mu Y, Lu J. Targeted therapy for HER2 positive breast cancer. J Hematol Oncol 2013, 6(1):38. 10.1186/1756-8722-6-38, 3703272, 23731980.
28. Braccini AL, Azria D, Thezenas S, Romieu G, Ferrero JM, Jacot W. Prognostic factors of brain metastases from breast cancer: impact of targeted therapies. Breast doi:10.1016/j.breast.2013.1005.1011.
29. Rafiyath S, Rasul M, Lee B, Wei G, Lamba G, Liu D. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. J Hematol Oncol 2012, 1(1):10.
30. Elbaz H, Stueckle T, Tse W, Rojanasakul Y, Dinu C. Digitoxin and its analogs as novel cancer therapeutics. Exp Hematol Oncol 2012, 1(1):4. 10.1186/2162-3619-1-4, 3506989, 23210930.
31. Xu D, Wang Q, Jiang Y, Zhang Y, Vega-SaenzdeMiera E, Osman I, Dai W. Roles of Polo-like kinase 3 in suppressing tumor angiogenesis. Exp Hematol Oncol 2012, 1(1):5. 10.1186/2162-3619-1-5, 3506990, 23210979.
32. Beklemisheva AA, Fang Y, Feng J, Ma X, Dai W, Chiao JW. Epigenetic mechanism of growth inhibition induced by phenylhexyl isothiocyanate in prostate cancer cells. Anticancer Res 2006, 26(2A):1225-1230.
33. Wang LG, Liu XM, Fang Y, Dai W, Chiao FB, Puccio GM, Feng J, Liu D, Chiao JW. De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol 2008, 33(2):375-380.
34. Wang LG, Beklemisheva A, Liu XM, Ferrari AC, Feng J, Chiao JW. Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer. Mol Carcinog 2007, 46(1):24-31. 10.1002/mc.20258, 16921492.
35. Cang S, Feng J, Konno S, Han L, Liu K, Sharma SC, Choudhury M, Chiao JW. Deficient histone acetylation and excessive deacetylase activity as epigenomic marks of prostate cancer cells. In: Int J Oncol 2009, 35:1417-1422.
36. Zou Y, Ma X, Huang Y, Hong L, Chiao J-W. Effect of phenylhexyl isothiocyanate on aberrant histone H3 methylation in primary human acute leukemia. J Hematol Oncol 2012, 5(1):36. 10.1186/1756-8722-5-36, 3413588, 22747680.
37. Liu K, Cang S, Ma Y, Chiao JW. Synergistic effect of paclitaxel and epigenetic agent phenethyl isothiocyanate on growth inhibition, cell cycle arrest and apoptosis in breast cancer cells. Cancer Cell Int 2013, 13(1):10. 10.1186/1475-2867-13-10, 3637186, 23388416.
38. Ma X, Fang Y, Beklemisheva A, Dai W, Feng J, Ahmed T, Liu D, Chiao JW. Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells. Int J Oncol 2006, 28(5):1287-1293.
39. Wade PA. Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum Mol Genet 2001, 10(7):693-698. 10.1093/hmg/10.7.693, 11257101.
40. Lu Q, Lin X, Feng J, Zhao X, Gallagher R, Lee MY, Chiao JW, Liu D. Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways. J Hematol Oncol 2008, 1:6. 10.1186/1756-8722-1-6, 2438442, 18577263.
41. Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP. HDAC6 is a microtubule-associated deacetylase. Nature 2002, 417(6887):455-458. 10.1038/417455a, 12024216.
42. Lindqvist A, van ZW, Karlsson RC, Wolthuis RM. Cyclin B1-Cdk1 activation continues after centrosome separation to control mitotic progression. PLoS Biol 2007, 5(5):e123. 10.1371/journal.pbio.0050123, 1858714, 17472438.
43. Chaitanya G, Alexander J, Babu P. PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun Signal 2010, 8(1):31. 10.1186/1478-811X-8-31, 3022541, 21176168.
44. Piperno G, LeDizet M, Chang XJ. Microtubules containing acetylated alpha-tubulin in mammalian cells in culture. J Cell Biol 1987, 104(2):289-302. 10.1083/jcb.104.2.289, 2114420, 2879846.
45. Mi L, Xiao Z, Hood BL, Dakshanamurthy S, Wang X, Govind S, Conrads TP, Veenstra TD, Chung FL. Covalent binding to tubulin by isothiocyanates. A mechanism of cell growth arrest and apoptosis. J Biol Chem 2008, 283(32):22136-22146. 10.1074/jbc.M802330200, 2494917, 18524779.
46. Dowdy SC, Jiang S, Zhou XC, Hou X, Jin F, Podratz KC, Jiang SW. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther 2006, 5(11):2767-2776. 10.1158/1535-7163.MCT-06-0209, 17121923.
47. Xiao D, Powolny AA, Moura MB, Kelley EE, Bommareddy A, Kim SH, Hahm ER, Normolle D, Van Houten B, Singh SV. Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated death of human prostate cancer cells. J Biol Chem 2010, 285(34):26558-26569. 10.1074/jbc.M109.063255, 2924093, 20571029.
48. Xiao D, Singh SV. p66Shc is indispensable for phenethyl isothiocyanate-induced apoptosis in human prostate cancer cells. Cancer Res 2010, 70(8):3150-3158. 10.1158/0008-5472.CAN-09-4451, 2855757, 20354186.
49. Xiao D, Singh SV. Phenethyl isothiocyanate sensitizes androgen-independent human prostate cancer cells to docetaxel-induced apoptosis in vitro and in vivo. Pharm Res 2010, 27(4):722-731. 10.1007/s11095-010-0079-9, 2837783, 20182772.
50. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006, 10(3):241-252. 10.1016/j.ccr.2006.08.009, 16959615.
51. Badia E, Oliva J, Balaguer P, Cavailles V. Tamoxifen resistance and epigenetic modifications in breast cancer cell lines. Curr Med Chem 2007, 14(28):3035-3045. 10.2174/092986707782794023, 2789301, 18220739.
52. Thomas S, Thurn KT, Bicaku E, Marchion DC, Munster PN. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res Treat 2011, 130(2):437-447. 10.1007/s10549-011-1364-y, 3760725, 21298336.